Search research articles
Contact Us
Filters
Showing results (191-200 of 224) with videos related to
Page
of 23
Sort By:
Leukemia & Lymphoma
|
June 28, 2001
Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481)
P H Wiernik, T Leong, M M Oken, et al.
International Journal of Technology Assessment in Health Care
|
October 1, 1996
Results of the economic evaluation of the first study. A multinational prospective economic evaluation. FIRST Investigators. Flolan International Randomized Survival Trial
K A Schulman, M Buxton, H Glick, et al.
Cancer Treatment Reports
|
April 1, 1982
Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group
J H Glick, J M Barnes, R F Bakemeier, et al.
Leukemia & Lymphoma
|
August 26, 1998
Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Study (PE481)
P H Wiernik, D F Moore, J M Bennett, et al.
Cancer Clinical Trials
|
January 1, 1981
Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum
M M Kligerman, A L Blumberg, J H Glick, et al.
Leukemia & Lymphoma
|
October 1, 1994
Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma
J P Colgan, J Andersen, T M Habermann, et al.
Cancer Treatment Reports
|
December 1, 1982
Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas
M J O'Connell, J Anderson, J M Merrill, et al.
Annals of Internal Medicine
|
October 1, 1984
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study
R F Bakemeier, J R Anderson, W Costello, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2003
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial
David B Duggan, Gina R Petroni, Jeffrey L Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial
J H Glick, M L Young, D Harrington, et al.
Page
of 23
Search research articles
Search
Showing results (191-200 of 224) with videos related to
Sort By:
Page
of 23
Leukemia & Lymphoma
|
June 28, 2001
Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481)
P H Wiernik, T Leong, M M Oken, et al.
International Journal of Technology Assessment in Health Care
|
October 1, 1996
Results of the economic evaluation of the first study. A multinational prospective economic evaluation. FIRST Investigators. Flolan International Randomized Survival Trial
K A Schulman, M Buxton, H Glick, et al.
Cancer Treatment Reports
|
April 1, 1982
Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group
J H Glick, J M Barnes, R F Bakemeier, et al.
Leukemia & Lymphoma
|
August 26, 1998
Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Study (PE481)
P H Wiernik, D F Moore, J M Bennett, et al.
Cancer Clinical Trials
|
January 1, 1981
Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum
M M Kligerman, A L Blumberg, J H Glick, et al.
Leukemia & Lymphoma
|
October 1, 1994
Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma
J P Colgan, J Andersen, T M Habermann, et al.
Cancer Treatment Reports
|
December 1, 1982
Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas
M J O'Connell, J Anderson, J M Merrill, et al.
Annals of Internal Medicine
|
October 1, 1984
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study
R F Bakemeier, J R Anderson, W Costello, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2003
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial
David B Duggan, Gina R Petroni, Jeffrey L Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial
J H Glick, M L Young, D Harrington, et al.
Page
of 23